#### PATENT COOPERATION 1 KEATY

#### From the INTERNATIONAL BUREAU

#### PCT

#### **MOTIFICATION OF ELECTION**

(PCT Rule 61.2)

Commissioner **US Department of Commerce** United States Patent and Trademark

Office, PCT

2011 South Clark Place Room

CP2/5C24

Arlington, VA 22202

**ETATS-UNIS D'AMERIQUE** 

in its capacity as elected Office

Date of mailing (day/month/year) 07 February 2001 (07.02.01)

International application No. PCT/AU00/00643

International filing date (day/month/year)

07 June 2000 (07.06.00)

Applicant's or agent's file reference

2831WOP00

Priority date (day/month/year) 07 June 1999 (07.06.99)

Applicant

CLANCY, Robert et al

1.	The designated Office is hereby notified of its election made:
	in the demand filed with the International Preliminary Examining Authority on:
	22 December 2000 (22.12.00)
	in a notice effecting later election filed with the International Bureau on:
2.	The election X was
	was not
	made before the expiration of 19 months from the priority date or, where Rule 32 applies, within the time limit under Rule 32.2(b).
	· · · · · · · · · · · · · · · · · · ·
l	

The International Bureau of ₩IPO 34, chemin des Colombettes 1211 Geneva 20, Switzerland

**Authorized officer** 

A. Karkachi

Telephone No.: (41-22) 338.83.38

Form PCT/iB/331 (July 1992)

Facsimile No.: (41-22) 740.14.35

AU0000643

### PATENT COOPERATION TREATY

### **PCT**

REC'D 0 9 OCT 2001

## INTERNATIONAL PRELIMINARY EXAMINATION REPORT (PCT Article 36 and Rule 70)

Applicant's or agent's file reference FOR FURTHER See Notification of Transmittal of International Preliminary 28317WOP00 DAA/JFO:NMT **ACTION** Examination Report (Form PCT/IPEA/416). International Filing Date (day/month/year) International Application No. Priority Date (day/month/year) PCT/ATION/006/13 7 June 2000

7 June 2000 / June 1999						
International Patent Classification (IPC) or national classification and IPC						
Int. Cl. <sup>7</sup> G01N 33/53, 33/68						
Applicant						
THE UNIVERSITY OF NEWCASTLE RESEA	RCH ASSOCIATES LIMITED et al.					
\.						
This international preliminary examination report I and is transmitted to the applicant according to Art.	has been prepared by this International Preliminary Examining Authority ticle 36.					
2. This REPORT consists of a total of 5 sheets, in	cluding this cover sheet.					
This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).						
These annexes consist of a total of sheet(s).	These annexes consist of a total of sheet(s).					
3. This report contains indications relating to the following i	tems:					
I X Basis of the report						
II Priority	II Priority					
III Non-establishment of opinion with regard to novelty, inventive step and industrial applicability						
IV Lack of unity of invention						
V Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement						
VI Certain documents cited						
VII Certain defects in the international ap	plication					
VIII X Certain observations on the international application						
Date of submission of the demand	Date of submission of the demand  Date of completion of the report					
22 December 2000	21 September 2001					
Name and mailing address of the IPEA/AU	Authorized Officer					
AUSTRALIAN PATENT OFFICE	1/1/4K//					
PO BOX 200, WODEN ACT 2606, AUSTRALIA						
E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929	NORMAN BLOM					
	Telephone No. (02) 6283 2238					

#### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

### PCT/AU00/00643

I.	Basis of the report
1.	With regard to the elements of the international application:*
	X the international application as originally filed.
	the description, pages, as originally filed,
	pages, filed with the demand,
	pages, received on with the letter of
	the claims, pages, as originally filed,
	pages , as amended (together with any statement) under Article 19,
	pages, filed with the demand,
	pages, received on with the letter of
	the drawings, pages, as originally filed,
	pages, filed with the demand,
	pages, received on with the letter of
	the sequence listing part of the description:
	pages , as originally filed
	pages , filed with the demand
_	pages, received on with the letter of
2.	With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.
	These elements were available or furnished to this Authority in the following language which is:
	the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
	the language of publication of the international application (under Rule 48.3(b)).
	the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).
3.	With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:
	contained in the international application in written form.
	filed together with the international application in computer readable form.
	furnished subsequently to this Authority in written form.
	furnished subsequently to this Authority in written form.  furnished subsequently to this Authority in computer readable form.
	The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the
	international application as filed has been furnished.
	The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished
4.	The amendments have resulted in the cancellation of:
	the description, pages
	the claims, Nos.
	the drawings, sheets/fig.
5.	This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**
*	Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).
**	Any replacement sheet containing such amendments must be referred to under item 1 and annexed to this report

International application No.

#### PCT/AU00/00643

v.	Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations
	and explanations supporting such statement

1.	Statement		
	Novelty (N)	Claims 1-19	YES
		Claims none	NO
	Inventive step (IS)	Claims 1-19	YES
		Claims none	NO
	Industrial applicability (IA)	Claims 1-19	YES
		Claims none	NO

2. Citations and explanations (Rule 70.7)

#### Novelty (N) and Inventive Step (IS): Claims 1-19

None of the documents cited in the ISR disclose a method of assessing potential susceptibility to development of ALTE and/or SIDS in a subject by determining the **immunoglobulin A (IgA) or immunoglobulin A1** (**IgA1)** level in a sample from the subject and comparing this IgA level with that of a predetermined standard in order to predict susceptibility to development of ALTE and/or SIDS.

The closest prior art is to be found in the following three documents:-

US 5556759 and US 5747266, both of which disclose an assay and method for screening newborns to determine risk of SIDS based on the detection of elevated IgM-anti-IgG (MAG) levels in newborns' serum within the first year of birth.

Pediatric Research (1993), 33 (6), 554-556 discloses that an abnormal (exaggerated and prolonged) immune response was seen in an infant who unexpectedly died from SIDS following a transient mild URTI. The IgA level in the saliva of this infant was found to rise in the 4th week of life and continued to rise in samples collected in the 6<sup>th</sup> and 8<sup>th</sup> week to a level 5 times higher than the age-related median level for 8 weeks of age. It is noted that the appearance of IgM and an increase in IgA in saliva is a normal event after URTI (page 555 column 2) and it is indicated that a previous control study had found that the IgA peak level during URTI periods (in three children under 6 months of age) did not exceed 0.020 g/L (see page 555 column 1) (this peak IgA concentration during URTI is at odds with the age-related reference IgA concentrations depicted in the shaded areas in Figure 1 (C), which shows a 90th percentile reference level of 0.050-0.060 g (IgA)/L for infants between the ages of 3-8 weeks). Several other potentially conditionary risk factors (page 556 column 1) were identified in this SIDS infant (including passive smoking (page 554 column 2), a transient mild URTI (abstract, page 554 column 1 and page 555 column 2) and pattern of infant feeding (page 554 column 1)). It is postulated that a disturbance in immune regulation and/or mucosal permeability may constitute a link in the chain of events that lead to respiratory arrest (page 554 column 1) or that an inappropriate or persistent mucosal immune response to antigen may activate vagal afferent nerve endings or chemoreceptors to induce reflex apnea (page 556 column 1).

The following documents cited in the ISR disclose that elevated levels of IgA or IgA producing cell were found in serum, lung lavage or tissues from various organs following post mortem investigations of victims of SIDS.

Pediatric Research (1992), 31 (4), 372-375 discloses that the number of IgA plasma cells in duodenal mucosa from SIDS cases was significantly more than that found in non-infectious controls but on the other hand the number of IgA plasma cells in infants who died of infections was significantly more than that of the SIDS cases (see page 373 Results). Further, although 90% of SIDS infants had definite signs and symptoms of an URTI none of these infections were judged to be sufficient to cause death (see page 373 column 2) (continued)

#### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/AU00/00643

VIII. Certain observations on the international application
The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:
Claim 19 is not clear because it purports to define a kit yet it does not specify a single component of this kit.

#### INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No.

PCT/AU00/00643

#### Supplemental Box

(To be used when the space in any of the preceding boxes is not sufficient)

Continuation of V. 2. Citations and explanations

Pediatr Allergy Immunol (1995), 6, 48-55 discloses that the number of IgA cells was higher in SIDS vs. controls in both the germinal centre and in the interfollicular area of the palatine tonsils, while no differences could be demonstrated in the mantle zone or in the reticular epithelium (page 52 column 1). It is indicated that the palatine tonsils are not part of the secretory immune system but may play an important role in priming the BALT and GALT lymphoid systems (see pages 48-49). It is indicated that SIDS might be due to an overreaction of the mucosal immune system to a common microbial factor (see page 53 column 2 lines 29-39).

Journal of Pathology (1995), 177, 415-421 discloses that peribronchial IgA expression was significantly increased in SIDS cases but that there was no significant difference in subpleural IgA expression between the SIDS group and controls (see page 419 column 1). This study also found that peribronchial IgA was the only immunoglobulin which showed increased expression in SIDS infants (see page 420) (which is indicated to be in conflict with reports of several other studies). It is indicated that increased IgA expression in peribronchial sites may contribute to pulmonary damage in SIDS (page 420).

BMJ (1989), 298, 23-26 discloses that victims of SIDS had grossly raised concentrations of IgG, IgM and to a lesser extent IgA compared with the controls. The mean IgA concentration in lung lavage samples taken from the SIDS group was significantly more than controls (7 g/mg total protein for SIDS victims compared with 3 g/mg in the controls) and pulmonary immunohistological staining revealed that the number of positively staining IgA bearing cells was significantly increased compared to controls (see Figures 2 and 3 and *Results* (page 24-25)).

J. Clin. Path., (1971), 24, 736-739 discloses that in 18%, 21% and 67% of cases of SIDS, serum levels of IgA, IgG and IgM respectively, were higher than levels found in normal infants.

The Lancet (1990), 335 (8683), 229-230 discloses that SIDS victims had significantly increased numbers of IgG, IgM and IgA producing cells compared with non-infectious controls whereas the numbers of Ig producing cells in the infants that died from pneumonia were much the same as those in SIDS victims. These findings are said to suggest the possibility of immunological overstimulation in the upper respiratory and gastrointestinal tracts which ultimately leads to hypoxia and death (see entire letter to the Editor).

#### INTERNATIONAL SEARCH REPORT

International application No.

PCT/AU00/00643

#### A. CLASSIFICATION OF SUBJECT MATTER

Int. Cl. 7: G01N 33/53, 33/68

According to International Patent Classification (IPC) or to both national classification and IPC

#### B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Derwent (WPAT), Medline and chemical abstracts. Keywords (iga, immunoglobulin a, sids, sudden infant death, apnea, apnoea, alte, saliva)

apnea, apno	ea, alte, saliva)				
C.	DOCUMENTS CONSIDERED TO BE RELEVA	NT			
Category*	Citation of document, with indication, where a	on of document, with indication, where appropriate, of the relevant passages			
Y	Pediatric Research (1993), 33 (6), 554-556 Case of Sudden Infant Death Syndrome, N (see entire article, particularly the Discussion	I. Gleeson et al.	1-8, 10-19		
Y	US 5556759 A (Beach P. G.) 17 September (see entire document, in particular column 33-49)	1-19			
Y	US 5747266 A (Beach P. G.) 5 May 1998 (see entire document, in particular column 35-51)	1-19			
x	Further documents are listed in the continua	tion of Box C X See patent fam	nily annex		
"A" document or or or or with another or with another or with another or with another or	ment defining the general state of the art which is onsidered to be of particular relevance er application or patent but published on or after nternational filing date ment which may throw doubts on priority claim(s)	"T" later document published after the inpriority date and not in conflict with understand the principle or theory understand the considered novel or cannot be conventive step when the document is document of particular relevance; the considered to involve an inventive combined with one or more other succombination being obvious to a person document member of the same pater."	the application but cited to inderlying the invention are claimed invention cannot insidered to involve an as taken alone are claimed invention cannot are step when the document is and documents, such son skilled in the art		
Date of the ac	ctual completion of the international search	Date of mailine of the international sear 25 AGUS. 2000			
	uiling address of the ISA/AU	Authorized officer	Now /		
AUSTRALIA	N PATENT OFFICE		VEE\//		

**NORMAN BLOM** 

E-mail address: pct@ipaustralia.gov.au Facsimile No. (02) 6285 3929

PO BOX 200, WODEN ACT 2606, AUSTRALIA

#### INTERNATIONAL SEARCH REPORT

International application No. PCT/AU00/00643

C (Continuat	tion). DOCUMENTS CONSIDERED TO BE RELEVANT	
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	BMJ (1998 January), 298, 23-26, Lung immunoglobulins in the sudden infant death syndrome, K. D. Forsyth et al. (see entire article, in particular the abstract, Introduction and Results and page 25	1-9,11-14, 16-19
	Journal of Pathology (1995), 177, 415-421, Pulmonary Eosinophilia in Sudden Infant	10-19
	Death Syndrome, J. A. Baxendine and I. E. Moore.	
Y	(see entire document, in particular Figure 1, page 419 column 1 and page 420 column 1)	1-9, 11-14, 16-19
	The Lancet (1990 January 27), 335 (8683), 229-230, Increased immune response in upper respiratory and digestive tracts in SIDS, P. S. Thrane et al.	
Y	(see entire Letter to the Editor)	1-19
	Pediatric Research (1992), 31 (4), 372-375, Sudden Infant Death Syndrome Victims Show Local Immunoglobulin M Response in Tracheal Wall and Immunoglobulin A Response in Duodenal Mucosa, L. Stoltenberg et al.	
Y	(see entire article, in particular the abstract, page 372, page 373 "Results", and page 374 column 2)	1-9, 11-14, 16-19
	Pediatr. Allergy Immunol. (1995), 6, 48-55, Changes in the concentration and distribution of immunoglobulin-producing cells in SIDS palatine tonsils, L. Stoltenberg	
Y	et al. (see entire article, in particular pages 48-49 and 52-53)	1-9, 11-14, 16-19
	J. Clin. Path. (1971), 24, 736-739, Sudden unexplained death in infancy and hyperimmunization, G. E. D. Urquhart et al.	
Y	(see entire article)	1-4, 8, 10-11, 14, 16-17, 19
	Basic and Clinical Immunology, Seventh Edition (1991), Edited by Daniel P. Stites and Abba I. Terr, published by Appleton & Lange (a division of Prentice-Hall International Inc.), Chapter 15, The Mucosal Immune System, Pages 175-186.	
Y	(see in particular page 179 and pages 183-184 column 1 "Mucosal Homing").	1-19
	Scand. J. Immunol. (1991), 33 (5), 533-541, The Variability of Immunoglobulins and Albumin in Salivary Secretions of Children, M. Gleeson et al.	
Y	(see page 533 column 1, page 536 column 2 to page 537 column 1 and the abstract)	1-19
	Clinics in Perinatology (1992), 19 (4), 809-838, Apparent Life-Threatening Events and Apnea of Infancy, J. G. Brooks	
A	(see page 819 "Clinical Presentation" (first paragraph), page 826 Table 15 "Acute Condition", page 829 "Management" (last paragraph)).	1
	Clinics in Perinatology, (1992), 19 (4), 861-869, Prospective Identification of the Risk of SIDS, D. C. Shannon	
Y	(see page 862 lines 9-11)	1

# INTERNATIONAL SEARCH REPORT Information on patent family members

International application No. PCT/AU00/00643

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report		* Come : mini :		Patent Family Member	
US	5747266	US	5556759		
US	5556759	US	5747266		
					END OF ANNEX